Clinical Trial Update: GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

GEN1042 is being evaluated in a Phase 1/2 safety study with indications across malignant solid tumors, including non-small cell lung cancer, with early signals …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Malignant Solid Tumor
• Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• GEN1042

Snippet

Sponsor: Genmab | Conditions: Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING